Regeneron IDs gene variant tied to NASH, partners with Alnylam

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) partnered with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to develop RNAi therapeutics that target the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene to

Read the full 246 word article

User Sign In